Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLI NASDAQ:DYAI NASDAQ:GNCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.86+1.7%$0.76$0.46▼$1.32$9.54M0.316,056 shs6,947 shsDYAIDyadic International$0.78-7.8%$0.78$0.65▼$1.35$30.92M1.17613,397 shs217,356 shsGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+2.16%+2.47%+23.19%-3.67%-28.57%DYAIDyadic International+8.91%+16.26%+17.84%+6.30%-7.76%GNCAGenocea Biosciences0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.86+1.7%$0.76$0.46▼$1.32$9.54M0.316,056 shs6,947 shsDYAIDyadic International$0.78-7.8%$0.78$0.65▼$1.35$30.92M1.17613,397 shs217,356 shsGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+2.16%+2.47%+23.19%-3.67%-28.57%DYAIDyadic International+8.91%+16.26%+17.84%+6.30%-7.76%GNCAGenocea Biosciences0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 2.00HoldN/AN/ADYAIDyadic International 2.33Hold$3.00283.63% UpsideGNCAGenocea Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BCLI, GNCA, and DYAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2026DYAIDyadic International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/ADYAIDyadic International$1.67M17.03N/AN/A$0.03 per share26.07GNCAGenocea Biosciences$1.91M0.00N/AN/A$0.47 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$11.62M-$1.64N/AN/AN/AN/AN/A-519.50%8/17/2026 (Estimated)DYAIDyadic International-$7.36M-$0.23N/AN/AN/A-192.40%-1,005.45%-77.64%8/12/2026 (Estimated)GNCAGenocea Biosciences-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/ALatest BCLI, GNCA, and DYAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026DYAIDyadic International-$0.04-$0.05-$0.01-$0.05$0.90 million$1.11 million3/25/2026Q4 2025DYAIDyadic International-$0.03-$0.06-$0.03-$0.06$1.34 million$0.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AGNCAGenocea BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.210.21DYAIDyadic International4.082.422.42GNCAGenocea Biosciences0.241.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%DYAIDyadic International27.95%GNCAGenocea Biosciences0.64%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics11.15%DYAIDyadic International20.90%GNCAGenocea Biosciences1.61%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics4011.04 million8.74 millionOptionableDYAIDyadic International736.44 million28.82 millionOptionableGNCAGenocea Biosciences7058.73 million57.79 millionNot OptionableBCLI, GNCA, and DYAI HeadlinesRecent News About These CompaniesGenocea Biosciences Inc.April 20, 2026 | barrons.comGenocea Biosciences – a Good Buy and Hold StockMarch 19, 2024 | fxempire.comFGenocea Biosciences Inc GNCAQJanuary 5, 2024 | morningstar.comMBD FACSVerse Flow Cytometer from BD BiosciencesMay 22, 2023 | news-medical.netNMerck to buy Prometheus Biosciences for about $11 blnApril 25, 2023 | health.economictimes.indiatimes.comGNCAQ Genocea Biosciences, Inc.January 26, 2023 | seekingalpha.com3 Health Care Stocks Under $10 to Trade for BreakoutsAugust 31, 2022 | thestreet.comGenocea Biosciences, Inc. (GNCA)August 9, 2022 | uk.finance.yahoo.comwhy Genocea Biosciences Inc. [GNCA] is a Good Choice for Investors After New Price Target of $3.08May 31, 2022 | dbtnews.comDGRPN, GNCA and LAB among mid-day moversMay 27, 2022 | seekingalpha.comThinking about buying stock in Geovax Labs, Genocea Biosciences, Motus GI, Express, or Caleres?May 25, 2022 | mytwintiers.comMGenocea Biosciences to shut downMay 25, 2022 | finance.yahoo.comGenocea ending operations, laying off all employeesMay 24, 2022 | mmm-online.comMGenocea Closes Shop, Delists From NASDAQMay 24, 2022 | finance.yahoo.comThree weeks after layoffs, Genocea shuts down entirelyMay 24, 2022 | finance.yahoo.comGenocea stock crashes 64% on winding down of operations, Nasdaq delistingMay 24, 2022 | seekingalpha.comGenocea Announces Wind Down of Operations and Delisting From NASDAQMay 24, 2022 | finance.yahoo.comGenocea Biosciences Inc. [GNCA] moved up 33.85: Why It’s ImportantMay 16, 2022 | dbtnews.comDGenocea cuts two-thirds of staff, explores a saleMay 2, 2022 | finance.yahoo.comGenocea stock plunges on cutting workforce by 65% and exploring sale or merger alternatives; Stifel cuts PT to $0.16April 29, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCLI, GNCA, and DYAI Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$0.86 +0.01 (+1.71%) As of 03:47 PM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Dyadic International NASDAQ:DYAI$0.78 -0.07 (-7.85%) Closing price 04:00 PM EasternExtended Trading$0.80 +0.02 (+2.05%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Genocea Biosciences NASDAQ:GNCAGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
